Three Diabetes Drugs Linked to Ketoacidosis, FDA Warns

(MedPage Today) -- FDA targets SGLT2 inhibitors canagliflozin, dapagliflozin, and empagliflozin.
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news